Annexon stock is trading -85.71% below its average target price of $15.4 after dropping -57.4% during today's afternoon session. Analysts are giving the small-cap Pharmaceutical company an average rating of buy and target prices ranging from $8.0 to $24.0 per share.
The stock has an average amount of shares sold short at 5.2%, and a short ratio of 6.19. At 2.2%, the company's rate of insider ownership does not indicate that management is deeply invested in the company. Finally, we also note that a significant number of institutional investors are invested in the stock, with 100.7% of Annexon's shares being owned by this investor type.
Institutions Invested in Annexon
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Alerce Investment Management, L.P. | 13% | 7,056,024 | $15,523,253 |
| 2023-03-31 | Bain Capital Life Sciences Investors, LLC | 9% | 4,886,616 | $10,750,555 |
| 2023-03-31 | Adage Capital Partners GP L.L.C. | 7% | 3,549,975 | $7,809,945 |
| 2023-03-31 | Redmile Group, LLC | 7% | 3,503,190 | $7,707,018 |
| 2023-03-31 | VR Adviser, LLC | 6% | 3,220,050 | $7,084,110 |
| 2023-03-31 | Federated Hermes, Inc. | 6% | 3,057,800 | $6,727,160 |
| 2023-03-31 | Citadel Advisors Llc | 5% | 2,413,117 | $5,308,857 |
| 2023-03-31 | Eventide Asset Management LLC | 4% | 1,867,250 | $4,107,950 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 3% | 1,569,971 | $3,453,936 |
| 2023-03-31 | GMT Capital Corp | 3% | 1,408,697 | $3,099,133 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Annexon.
